Belite Bio, Inc Share Price & Technical Analysis
BLTE · $137.2 (-0.05%)
Healthcare / Biotechnology
$137.2
-0.05%
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt dis…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-13% return in May, -6% avg return in past 3 year May month.
-11% return in 2026, 80% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 6% | 14% | -16% | -2% | -13% | – | – | – | – | – | – | – | -11% |
| 25 | -8% | 0% | 14% | -6% | 6% | -11% | 14% | -3% | 19% | 43% | 28% | 4% | 101% |
| 24 | -5% | 6% | -17% | 5% | 21% | -7% | 8% | -1% | -4% | 42% | -4% | 0% | 43% |
| 23 | 0% | 14% | -9% | -4% | -44% | -11% | 67% | 51% | -5% | 18% | 12% | 8% | 98% |
| 22 | – | – | – | -15% | 64% | 106% | 5% | -9% | 2% | -11% | 13% | -7% | 149% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.19B
P/E ratio
—
52W high
$200.0
52W low
$56.10
Volume
91,690
Beta
-1.19
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Belite Bio, Inc share price today?
- Belite Bio, Inc (BLTE) last traded around $137.2 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BLTE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BLTE. Download the app for real-time alerts.
- How can I analyze Belite Bio, Inc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.